A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors

Clinical Trials, Metastatic Castration Resistant Prostate Cancer (MCRPC)

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT05268666
Phase: Phase 1|Phase 2
Trial Summary: The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of JBI-802 in patients with Advanced Solid Tumors.The efficacy of the – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Jubilant Therapeutics Inc.
Acronym:

Pin It on Pinterest